Literature DB >> 27751686

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Jeffrey J Tosoian1, Michael A Gorin2, Steven P Rowe3, Darian Andreas2, Zsolt Szabo3, Kenneth J Pienta2, Martin G Pomper3, Tamara L Lotan4, Ashley E Ross2.   

Abstract

Entities:  

Keywords:  Immunohistochemistry (IHC); Metastatic prostate cancer; Neuroendocrine prostate cancer; Positron emission tomography/computed tomography (PET/CT) imaging; Prostate-specific membrane antigen

Mesh：

Substances：

Year:  2016        PMID： 27751686      PMCID： PMC5572129          DOI： 10.1016/j.clgc.2016.09.002

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  16 in total

1.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Authors:  Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

3.  Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.

Authors:  Partha Sarathi Chakraborty; Madhavi Tripathi; Krishan Kant Agarwal; Rajeev Kumar; Maneesh Kumar Vijay; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2015-02       Impact factor: 7.794

4.  High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.

Authors:  Sarah Minner; Corinna Wittmer; Markus Graefen; Georg Salomon; Thomas Steuber; Alexander Haese; Hartwig Huland; Carsten Bokemeyer; Emre Yekebas; Judith Dierlamm; Stefan Balabanov; Ergin Kilic; Waldemar Wilczak; Ronald Simon; Guido Sauter; Thorsten Schlomm
Journal:  Prostate       Date:  2010-08-31       Impact factor: 4.104

5.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Molecular characterization of prostatic small-cell neuroendocrine carcinoma.

Authors:  Nigel Clegg; Camari Ferguson; Lawrence D True; Hugh Arnold; Alec Moorman; Janna E Quinn; Robert L Vessella; Peter S Nelson
Journal:  Prostate       Date:  2003-04-01       Impact factor: 4.104

Review 7.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

8.  Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.

Authors:  Donna E Hansel; Masashi Nakayama; Jun Luo; Abde M Abukhdeir; Ben H Park; Charles J Bieberich; Jessica L Hicks; Mario Eisenberger; William G Nelson; Jasek L Mostwin; Angelo M De Marzo
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

9.  Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Authors:  Harrison Tsai; Carlos L Morais; Mohammed Alshalalfa; Hsueh-Li Tan; Zaid Haddad; Jessica Hicks; Nilesh Gupta; Jonathan I Epstein; George J Netto; William B Isaacs; Jun Luo; Rohit Mehra; Robert L Vessella; R Jeffrey Karnes; Edward M Schaeffer; Elai Davicioni; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2015-08-05       Impact factor: 12.531

10.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488
View more
  23 in total

1.  PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  Eur Urol       Date:  2017-11-11       Impact factor: 20.096

2.  PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Authors:  Mariya Shapovalova; John K Lee; Yingming Li; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Cancer Res       Date:  2019-09-17       Impact factor: 12.701

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

Review 4.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Authors:  Shankar Siva; Cristian Udovicich; Ben Tran; Homi Zargar; Declan G Murphy; Michael S Hofman
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

5.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

6.  Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

Authors:  Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Clin Cancer Res       Date:  2019-11-15       Impact factor: 12.531

Review 7.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 8.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 9.  Recent updates and developments in PET imaging of prostate cancer.

Authors:  Steven P Rowe; Geoffrey B Johnson; Martin G Pomper; Michael A Gorin; Spencer C Behr
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 10.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Radiologe       Date:  2018-03       Impact factor: 0.635
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.